Neuralstem Archives | Be Korea-savvy
Neuralstem Awarded Phase I SBIR Contract to Support Research into Neural Stem Cell Therapy for Severe Traumatic Brain Injury

Neuralstem Awarded Phase I SBIR Contract to Support Research into Neural Stem Cell Therapy for Severe Traumatic Brain Injury

GERMANTOWN, Md., Jun. 11 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) contract by the Department of Defense (DoD). The award of $150,000 will support the Company’s ongoing efforts to develop its [...]

Neuralstem’s NSI-566 Stem Cell Therapy Confers Neurological Improvement in Spinal Cord Injury Patients with Complete Paraplegia

Neuralstem’s NSI-566 Stem Cell Therapy Confers Neurological Improvement in Spinal Cord Injury Patients with Complete Paraplegia

GERMANTOWN, Md., Jun. 4 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the results from a study published in the journal Cell Stem Cell that support the potential of transplanted NSI-566, a human spinal cord-derived neural stem cell line (HSSC) to benefit patients with chronic [...]

Neuralstem to Participate at the BIO 2018 International Convention

Neuralstem to Participate at the BIO 2018 International Convention

GERMANTOWN, Md., May 29 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that Karl Johe, PhD, Chief Scientific Officer of Neuralstem, will be providing a Company overview during the 2018 BIO International Convention in Boston, Massachusetts, on Monday, June 4, 2018 at 3:30pm ET.  A [...]

Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results

Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results

GERMANTOWN, Md., May 15 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, provides a business update and reported its financial results for the first quarter ended March 31, 2018 . “We remain committed to the development of NSI-566, our [...]

Neuralstem Announces Publication of Long-Term Follow-up Data on ALS in the Annals of Clinical and Translational Neurology

Neuralstem Announces Publication of Long-Term Follow-up Data on ALS in the Annals of Clinical and Translational Neurology

GERMANTOWN, Md., May 3 (Korea Bizwire) —  Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the results from a study published in the Annals of Clinical and Translational Neurology that support the potential of transplanted human spinal cord-derived neural stem cells (HSSC) to stabilize functioning of amyotrophic lateral [...]

Neuralstem to Present Clinical Update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy Investor Day

Neuralstem to Present Clinical Update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy Investor Day

GERMANTOWN, Md., Apr. 11 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced Karl Johe, Ph.D, Chief Scientific Officer of Neuralstem, will be providing a clinical update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy Investor Day at the Metropolitan Club in [...]

Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord Injury

Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord Injury

GERMANTOWN, Md., Apr. 10 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today announced that it completed the first surgery in the second, cervical injury cohort of a Phase 1 clinical trial in patients with chronic spinal cord injury [...]

Neuralstem Reports Year End 2017 Fiscal Results and Business Update

Neuralstem Reports Year End 2017 Fiscal Results and Business Update

GERMANTOWN, Md., Apr. 2 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, reported its financial results for the year ended December 31, 2017. “We remain committed to the development of NSI-566, our lead stem cell therapy candidate, and NSI-189 [...]

Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury

Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury

GERMANTOWN, Md., Mar. 13 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, highlighted the publication of a manuscript in Nature Medicine showing that NSI-566, Neuralstem’s lead cell therapy candidate, provided meaningful improvement in forelimb function in a non-human primate model of acute spinal cord injury. [...]

Neuralstem to Participate at Upcoming Investor Conferences

Neuralstem to Participate at Upcoming Investor Conferences

GERMANTOWN, Md., Mar. 12 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that members of the management team will participate at the following upcoming investor conferences:   B. Riley FBR, Inc. & Co. China Healthcare Investment & Partnering Symposium in Hangzhou, China, on Saturday, March [...]